14 February 2012

Herald Sun Journalist John Beveridge details how biotechnology companies are working to ‘fix many ailments’, with specific reference to promising results emerging from Starpharma’s diverse research portfolio.

The best thing about Starpharma is that it owns a genuine platform technology that is capable of spinning off multiple products across a range of different and highly lucrative areas.

It owns a forest of patents on dendrimers—tiny polymers which can be engineered to create many different results, such as making a drug water soluble or preventing the transmission of viruses and bacteria.

Chief executive Dr Jackie Fairley said the recent approval from the US Food and Drug Administration and European regulators for phase 3 trials of its VivaGel product later this year was a highly significant step in bringing the product to market.

10 February 2012

This Bioshares analysis provides insight into promising advancements within the Biotech sector in 2012. Starpharma is recognised for achieving a significant rise in shareprice and reaching exciting milestones in the development and pending commercialisation of its diverse research portfolio.

 

Download: Bioshares Issue 442 (pdf file, 27kb)

8 February 2012

Australian Financial Review Journalist Brendon Lau investigates how Australian biotech companies are attracting the attention of local and international investors.

There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.

Most of the capital is expected to be invested in the Australian market as our biotech sector is considered to be the most mature in the region following the resounding success of the likes of Mesoblast, Acrux and Starpharma Holdings, which have put Australia on the global biotech stage.

Retail shareholders strongly oversubscribed for their entitlements at recent capital raisings by Alchemia, Phosphagenics and Starpharma – the latter two attracting new overseas professional and high net-worth investors.

12 January 2012

Australian Financial Review Journalist Carrie LaFrenz reports: Emerging biotech Starpharma Holdings has been given the tick of approval from the US Federal and Drug Administration on the design of its Phase 3 clinical studies for its key VivaGel product, taking it one step closer to market.

Starpharma has a number of promising technologies and has caught the attention of some large investors. UK-based M&G Investments took a 6.7 per cent stake following the successful $32 million placement in November.

11 January 2012

Australian Life Scientist Journalist Tim Dean notes the significance of Starpharma's written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel^® under the FDA’s Special Protocol Assessment (SPA) scheme: Starpharma has kicked off the year with a tick from the US Food and Drug Administration for its study design for phase III trials of VivaGel under the FDA’s Special Protocol Assessment scheme.

 

Go to the article (external link)

11 January 2012

Rebecca Richardson of Finance News Network presents on Starpharma's written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel^® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

 

Go to the video (external link)

6 December 2011

Herald Sun Journalist John Beveridge takes a close look at why M&G made a significant investment in Starpharma and what it could mean for other buyers: ‘If you see a clever investor grabbing a stake in a company, there is no problem piggy-backing on their research and following them on board.’

 

Go to the article (external link)

29 November 2011

Australian Financial Review Journalist Brendon Lau investigates the activity of fund managers across a number of key stocks: Emerging biotech Starpharma Holdings has also found itself in demand by institutional investors in the wake of its recent capital raising.

The stock could re-rate, just as Mesoblast did, because M&G – one of the largest UK investment funds that is owned by Prudential Group – bought a 6.7 per cent stake in Starpharma.

M&G also became a major shareholder in Mesoblast in December last year and the stock has rallied around 80 per cent since.

27 November 2011

Wall Street Journal Reporter Gillian Tan investigates M&G’s stake in Starpharma: ‘M&G emerged with a 6.7 per cent stake in the company after participating in Starpharma’s $32m oversubscribed institutional placement which raised funds to –among other things — accelerate the commercialisation of its VivaGel product which will include a New Drug Application filing with the United States’ Food and Drug Administration.’

 

Go to the article (external link)

17 November 2011

Australian Financial Review Journalist Claire Stewart investigates Starpharma’s continued resilience in a difficult market, noting the significance of its $32m capital raising at market price: As market volatility shakes investors’ confidence, the share prices of many research and development-focused companies are suffering as a result of increasing concerns about capital availability and funding issues.

But for Starpharma, a $260 million pharmaceutical company that develops polymer – or dendrimer – nanotechnology, equity has not been an issue.

This week it raised $32 million through a share placement to institutional investors and it will launch a retail share purchase plan to raise an additional $3 million, opening on November 23.